Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Cash from Financing Activities (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Cash from Financing Activities for 9 consecutive years, with -$64000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 166.67% to -$64000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44000.0 through Dec 2025, down 99.95% year-over-year, with the annual reading at $44000.0 for FY2025, 99.95% down from the prior year.
  • Cash from Financing Activities hit -$64000.0 in Q4 2025 for Sutro Biopharma, down from $102000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $137.7 million in Q2 2023 to a low of -$5.7 million in Q3 2023.
  • Historically, Cash from Financing Activities has averaged $14.2 million across 5 years, with a median of $633000.0 in 2021.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 14164.1% in 2022 and later plummeted 166.67% in 2025.
  • Year by year, Cash from Financing Activities stood at $506000.0 in 2021, then skyrocketed by 2315.22% to $12.2 million in 2022, then plummeted by 125.57% to -$3.1 million in 2023, then soared by 99.23% to -$24000.0 in 2024, then plummeted by 166.67% to -$64000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for STRO at -$64000.0 in Q4 2025, $102000.0 in Q3 2025, and -$60000.0 in Q2 2025.